Skip to content
Open access

Three-year survival in patients with cT4N0 breast cancer after neoadjuvant systemic therapy according to the extent of axillary surgery

Sep 2026 · Malignant tumours · 0 citations · 14 references

Abstract

Purpose. To compare 3-year survival outcomes in patients with cT4N0M0 breast cancer who achieved ycN0 status after neoadjuvant systemic therapy (NAST), according to the extent of axillary surgery. Materials and Methods. This single-center, prospective, nonrandomized cohort study included a historical control group. Patients were stratified into three groups according to the extent of axillary surgery: ALND, SLNB alone, and SLNB with completion ALND (patients with metastases in sentinel lymph node who underwent completion ALND). Three-year locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Results. The study included 274 patients with cT4N0M0 breast cancer: the ALND group (n=110), the SLNB group (n=145), and the SLNB with completion ALND group (n=19). Median follow-up was 40.9 months (QR 32.1–53.2). The ALND and SLNB groups were comparable in age, histologic type, tumor grade, molecular subtype, and pathologic response. Locoregional recurrence occurred in 2.7% of patients in the ALND group and 2.8% in the SLNB group (p>0.999); distant metastases occurred in 10.9% and 9.0% (p=0.664); and death occurred in 11.8% and 5.5% (p=0.106), respectively. Three-year LRRFS was 98.0% (95% CI 95.2–100%) in the ALND group versus 96.9% (95% CI 93.4–100%) in the SLNB group (p=0.84); DFS was 91.6% (95% CI 86.2–97.4%) versus 90.7% (95% CI 85.4– 96.4%) (p=0.92); and OS was 92.6% (95% CI 87.4–98.0%) versus 97.2% (95% CI 94.1–100%) (p=0.82). No statistically significant differences were observed between groups for any survival endpoint. Conclusion . In patients with cT4N0M0 breast cancer who achieve ycN0 status after neoadjuvant systemic therapy, 3-year survival outcomes after SLNB are comparable to those after ALND, supporting the oncologic safety of axillary surgery deescalation in carefully selected patients within this population.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.